Nyrada (ASX:NYR) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nyrada's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. Nyrada's average Total Assets over the quarter that ended in Dec. 2023 was A$5.11 Mil. Therefore, Nyrada's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Nyrada Gross-Profit-to-Asset % Historical Data

The historical data trend for Nyrada's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Gross-Profit-to-Asset % Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Nyrada's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Nyrada's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nyrada's Gross-Profit-to-Asset % falls into.

Nyrada Gross-Profit-to-Asset % Calculation

Nyrada's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0	/	( (12.014	+	5.165)	/ 2 )
	=	0	/	8.5895
	=	0.00 %

Nyrada's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (5.165	+	5.063)	/ 2 )
	=	0	/	5.114
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Nyrada Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nyrada's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines